img

Global Xeljanz (tofacitnib) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Xeljanz (tofacitnib) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
Xeljanz (tofacitnib) Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Xeljanz (tofacitnib) Drug market is projected to reach US$ 1119.5 million in 2029, increasing from US$ 1754 million in 2022, with the CAGR of -5.7% during the period of 2024 to 2029. Demand from Rheumatoid Arthritis and Psoriatic Arthritis are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Xeljanz (tofacitnib) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pfizer
Segment by Type
Tablets
Extended-release Tablets

Segment by Application


Rheumatoid Arthritis
Psoriatic Arthritis
Other

Segment by Region


North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Xeljanz (tofacitnib) Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Xeljanz (tofacitnib) Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Xeljanz (tofacitnib) Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Xeljanz (tofacitnib) Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Xeljanz (tofacitnib) Drug introduction, etc. Xeljanz (tofacitnib) Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Xeljanz (tofacitnib) Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Xeljanz (tofacitnib) Drug Market Overview
1.1 Xeljanz (tofacitnib) Drug Product Overview
1.2 Xeljanz (tofacitnib) Drug Market Segment by Type
1.2.1 Tablets
1.2.2 Extended-release Tablets
1.3 Global Xeljanz (tofacitnib) Drug Market Size by Type
1.3.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2024)
2 Global Xeljanz (tofacitnib) Drug Market Competition by Company
2.1 Global Top Players by Xeljanz (tofacitnib) Drug Sales (2018-2024)
2.2 Global Top Players by Xeljanz (tofacitnib) Drug Revenue (2018-2024)
2.3 Global Top Players by Xeljanz (tofacitnib) Drug Price (2018-2024)
2.4 Global Top Manufacturers Xeljanz (tofacitnib) Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Xeljanz (tofacitnib) Drug Market Competitive Situation and Trends
2.5.1 Xeljanz (tofacitnib) Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Xeljanz (tofacitnib) Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Xeljanz (tofacitnib) Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Xeljanz (tofacitnib) Drug Market
2.8 Key Manufacturers Xeljanz (tofacitnib) Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Xeljanz (tofacitnib) Drug Status and Outlook by Region
3.1 Global Xeljanz (tofacitnib) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Xeljanz (tofacitnib) Drug Historic Market Size by Region
3.2.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2018-2024)
3.2.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Region
3.3.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2024-2029)
3.3.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Xeljanz (tofacitnib) Drug by Application
4.1 Xeljanz (tofacitnib) Drug Market Segment by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Psoriatic Arthritis
4.1.3 Other
4.2 Global Xeljanz (tofacitnib) Drug Market Size by Application
4.2.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2024)
5 North America Xeljanz (tofacitnib) Drug by Country
5.1 North America Xeljanz (tofacitnib) Drug Historic Market Size by Country
5.1.1 North America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2024)
5.2 North America Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
5.2.1 North America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
6 Europe Xeljanz (tofacitnib) Drug by Country
6.1 Europe Xeljanz (tofacitnib) Drug Historic Market Size by Country
6.1.1 Europe Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2024)
6.2 Europe Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
6.2.1 Europe Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Xeljanz (tofacitnib) Drug by Region
7.1 Asia-Pacific Xeljanz (tofacitnib) Drug Historic Market Size by Region
7.1.1 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Xeljanz (tofacitnib) Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Value by Region (2024-2029)
8 Latin America Xeljanz (tofacitnib) Drug by Country
8.1 Latin America Xeljanz (tofacitnib) Drug Historic Market Size by Country
8.1.1 Latin America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2024)
8.2 Latin America Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
8.2.1 Latin America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Xeljanz (tofacitnib) Drug by Country
9.1 Middle East and Africa Xeljanz (tofacitnib) Drug Historic Market Size by Country
9.1.1 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Pfizer Xeljanz (tofacitnib) Drug Products Offered
10.1.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Xeljanz (tofacitnib) Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Xeljanz (tofacitnib) Drug Industrial Chain Analysis
11.4 Xeljanz (tofacitnib) Drug Market Dynamics
11.4.1 Xeljanz (tofacitnib) Drug Industry Trends
11.4.2 Xeljanz (tofacitnib) Drug Market Drivers
11.4.3 Xeljanz (tofacitnib) Drug Market Challenges
11.4.4 Xeljanz (tofacitnib) Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Xeljanz (tofacitnib) Drug Distributors
12.3 Xeljanz (tofacitnib) Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Tablets
Table 2. Major Company of Extended-release Tablets
Table 3. Global Xeljanz (tofacitnib) Drug Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 4. Global Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (K Units)
Table 5. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type (2018-2024)
Table 6. Global Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US& Million)
Table 7. Global Xeljanz (tofacitnib) Drug Market Share in Value by Type (2018-2024)
Table 8. Global Xeljanz (tofacitnib) Drug Price by Type (2018-2024) & (USD/Unit)
Table 9. Global Xeljanz (tofacitnib) Drug Sales by Type (2024-2029) & (K Units)
Table 10. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type (2024-2029)
Table 11. Global Xeljanz (tofacitnib) Drug Sales by Type (2024-2029) & (US$ Million)
Table 12. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type (2024-2029)
Table 13. Global Xeljanz (tofacitnib) Drug Price by Type (2024-2029) & (USD/Unit)
Table 14. North America Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (K Units)
Table 15. North America Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe Xeljanz (tofacitnib) Drug Sales (K Units) by Type (2018-2024)
Table 17. Europe Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific Xeljanz (tofacitnib) Drug Sales (K Units) by Type (2018-2024)
Table 19. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America Xeljanz (tofacitnib) Drug Sales (K Units) by Type (2018-2024)
Table 21. Latin America Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa Xeljanz (tofacitnib) Drug Sales (K Units) by Type (2018-2024)
Table 23. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Global Xeljanz (tofacitnib) Drug Sales by Company (2018-2024) & (K Units)
Table 25. Global Xeljanz (tofacitnib) Drug Sales Share by Company (2018-2024)
Table 26. Global Xeljanz (tofacitnib) Drug Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global Xeljanz (tofacitnib) Drug Revenue Share by Company (2018-2024)
Table 28. Global Market Xeljanz (tofacitnib) Drug Price by Company (2018-2024) & (USD/Unit)
Table 29. Global Xeljanz (tofacitnib) Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Xeljanz (tofacitnib) Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Xeljanz (tofacitnib) Drug as of 2022)
Table 32. Date of Key Manufacturers Enter into Xeljanz (tofacitnib) Drug Market
Table 33. Key Manufacturers Xeljanz (tofacitnib) Drug Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Xeljanz (tofacitnib) Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 36. Global Xeljanz (tofacitnib) Drug Sales by Region (2018-2024) & (K Units)
Table 37. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2018-2024)
Table 38. Global Xeljanz (tofacitnib) Drug Sales by Region (2018-2024) & (US$ Million)
Table 39. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2018-2024)
Table 40. Global Xeljanz (tofacitnib) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 41. Global Xeljanz (tofacitnib) Drug Sales by Region (2024-2029) & (K Units)
Table 42. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2024-2029)
Table 43. Global Xeljanz (tofacitnib) Drug Sales by Region (2024-2029) & (US$ Million)
Table 44. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2024-2029)
Table 45. Global Xeljanz (tofacitnib) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)
Table 46. Global Xeljanz (tofacitnib) Drug Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 47. Global Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (K Units)
Table 48. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application (2018-2024)
Table 49. Global Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 50. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application (2018-2024)
Table 51. Global Xeljanz (tofacitnib) Drug Price by Application (2018-2024) & (USD/Unit)
Table 52. Global Xeljanz (tofacitnib) Drug Sales by Application (2024-2029) & (K Units)
Table 53. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application (2024-2029)
Table 54. Global Xeljanz (tofacitnib) Drug Sales by Application (2024-2029) & (US$ Million)
Table 55. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application (2024-2029)
Table 56. Global Xeljanz (tofacitnib) Drug Price by Application (2024-2029) & (USD/Unit)
Table 57. North America Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) (K Units)
Table 58. North America Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) (K Units)
Table 60. Europe Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) (K Units)
Table 62. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) (K Units)
Table 64. Latin America Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) (K Units)
Table 66. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. North America Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (K Units)
Table 68. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2018-2024)
Table 69. North America Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (US$ Million)
Table 70. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2018-2024)
Table 71. North America Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (K Units)
Table 72. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2024-2029)
Table 73. North America Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (US$ Million)
Table 74. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2024-2029)
Table 75. Europe Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (K Units)
Table 76. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2018-2024)
Table 79. Europe Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (K Units)
Table 80. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2024-2029)
Table 81. Europe Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (US$ Million)
Table 82. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2024-2029)
Table 83. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2018-2024) & (K Units)
Table 84. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2024-2029) & (K Units)
Table 88. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2024-2029)
Table 89. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2024-2029) & (US$ Million)
Table 90. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2024-2029)
Table 91. Latin America Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (K Units)
Table 92. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (K Units)
Table 96. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2024-2029)
Table 97. Latin America Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (US$ Million)
Table 98. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2024-2029)
Table 99. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (K Units)
Table 100. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (K Units)
Table 104. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Country (2024-2029)
Table 105. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2024-2029) & (US$ Million)
Table 106. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Country (2024-2029)
Table 107. Pfizer Company Information
Table 108. Pfizer Introduction and Business Overview
Table 109. Pfizer Xeljanz (tofacitnib) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 110. Pfizer Xeljanz (tofacitnib) Drug Product
Table 111. Pfizer Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. Xeljanz (tofacitnib) Drug Market Trends
Table 115. Xeljanz (tofacitnib) Drug Market Drivers
Table 116. Xeljanz (tofacitnib) Drug Market Challenges
Table 117. Xeljanz (tofacitnib) Drug Market Restraints
Table 118. Xeljanz (tofacitnib) Drug Distributors List
Table 119. Xeljanz (tofacitnib) Drug Downstream Customers
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Xeljanz (tofacitnib) Drug Product Picture
Figure 2. Global Xeljanz (tofacitnib) Drug Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Xeljanz (tofacitnib) Drug Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Xeljanz (tofacitnib) Drug Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Tablets
Figure 6. Global Tablets Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Extended-release Tablets
Figure 8. Global Extended-release Tablets Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Global Xeljanz (tofacitnib) Drug Sales by Type (2018-2029) & (US$ Million)
Figure 10. Global Xeljanz (tofacitnib) Drug Sales Market Share by Type in 2022 & 2029
Figure 11. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2022
Figure 12. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2022
Figure 13. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2022
Figure 14. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2022
Figure 17. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Xeljanz (tofacitnib) Drug Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Xeljanz (tofacitnib) Drug Revenue in 2022
Figure 23. Xeljanz (tofacitnib) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Rheumatoid Arthritis
Figure 25. Global Rheumatoid Arthritis Sales YoY Growth (2018-2029) & (K Units)
Figure 26. Product Picture of Psoriatic Arthritis
Figure 27. Global Psoriatic Arthritis Sales YoY Growth (2018-2029) & (K Units)
Figure 28. Product Picture of Other
Figure 29. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Global Xeljanz (tofacitnib) Drug Sales by Application (2018-2029) & (US$ Million)
Figure 31. Global Xeljanz (tofacitnib) Drug Sales Market Share by Application in 2022 & 2029
Figure 32. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2022
Figure 33. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2022
Figure 34. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2022
Figure 35. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2022
Figure 38. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Xeljanz (tofacitnib) Drug Manufacturing Cost Structure
Figure 43. Xeljanz (tofacitnib) Drug Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed